10 January 2018 - - Cambridge, Massachusetts-based biotechnology company Trieza Therapeutics, Inc. has named Jeno Gyuris, Ph.D. as chief scientific officer, the company said.
Gyuris brings 25 years of scientific leadership experience in the biopharmaceutical industry and will lead all aspects of Trieza's novel therapeutics discovery and development.
Gyuris will work closely with existing scientific and operational staff to grow Trieza from its current incubator footprint to a fully independent development-stage company. He will also take a key role in interactions with potential investors and strategic collaborators to advance the Trieza pipeline.
A veteran of the Cambridge biotech cluster, Gyuris has held a number of scientific leadership positions including chief scientific officer of Aveo Pharmaceuticals and executive VP, R and D, and chief scientific officer for Quiet Therapeutics.
He began his career in cancer biotherapeutics at Mitotix and held the role of vice president of molecular technologies after the company's acquisition by GPC Biotech.
Gyuris received his Ph.D. from the University of Szeged, Hungary, and completed a postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital.
Trieza Therapeutics is building a portfolio of immuno-modulatory oncolytic viruses as therapeutic candidates for cancer immunotherapy. The company's approach to stimulate anti-tumor immune responses is based on a novel virus platform that combines potent yet tumor-selective lysis with rapid, transient expression of engineered transgenes encoding immuno-modulatory agents.
Trieza's current portfolio of preclinical IOVs includes viruses expressing immune-stimulants, checkpoint inhibitors, and ligands for T-cell costimulatory or coinhibitory receptors.The company was formed in November 2016 as a spin-out from Potenza Therapeutics.